Endo Launches Authorized Generic Version of Amitiza® (lubiprostone) Capsules in the United States

IndustryPRwire - Endo International announced that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first authorized generic versions of Mallinckrodt's Amitiza® (lubiprostone) 8 mcg and 24 mcg capsules.

"This partnership brings the first Amitiza® generic to patients—giving them a cost-effective alternative," said Jon Holden, Senior Vice President and General Manager, Generics at Endo. "Par is proud to be a reliable, quality supplier that can help bring that choice to patients while expanding our product portfolio."

According to IQVIA™, Amitiza® capsule sales were approximately $427 million for the 12 months ended September 30, 2020. 

Amitiza® is a registered trademark of a Mallinckrodt company.

Related Posts

Subscribe Our Newsletter